Shares of Gilead Sciences Inc. were up 0.1% in premarket trading on Tuesday, the day after the drug maker said it will donate 450,000 doses of its COVID-19 antiviral Veklury to India, which is undergoing an unprecedented surge in coronavirus cases, illnesses, and deaths. Gilead will also provide technical support to its seven licensing partners in India that manufacture remdesivir, and it will donate the active pharmaceutical ingredient used to make redmesivir, which is now called Veklury in the U.S. Gilead’s stock is up 12.9% for the year, while the broader S&P 500 has gained 11.5%.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
